Key Points of the 2026 (Reiwa 8) Dispensing Remuneration Revision Explained Simply! New, Revised, and Abolished Items and Fee Schedule – Yakudoku

News Summary

An article explaining the key points of the 2026 (Reiwa 8) dispensing remuneration revision, including new, revised, and abolished items, and the fee schedule. As points of discussion for M&A and business succession in the pharmacy industry, the value of third-party succession for successor issues, the importance of early consideration from around age 60, and the significance of utilizing specialized healthcare industry advisors are suggested.

M&A Medical Editorial Department’s Perspective

The trends in the 2026 dispensing remuneration revision are directly linked to the revenue structure of pharmacy businesses, making them an indispensable factor when considering M&A and business succession. In particular, how evaluations for community support system premiums and home healthcare change will redefine the strengths and weaknesses of individual pharmacies and influence their business value. For example, a scheme where large chains with a network of stores above a certain size integrate small pharmacies with a focus on community-based and home-based care could leverage the advantages of both. It is predicted that strategic M&A, not just addressing “successor issues” but also capturing changes in the external environment such as remuneration revisions to enhance business sustainability, will become the mainstream for business succession in the future pharmacy industry.

Points Indicated by This News

• The significant impact of dispensing remuneration revisions on pharmacy business value and M&A strategy
• The possibility that changes in evaluations for community support and home healthcare will redefine the business strategies of individual pharmacies
• Expectations for synergy creation through M&A between large chains and community-focused pharmacies
• The importance of viewing remuneration revisions as an opportunity for strategic M&A to ensure business continuity and development

Practical Questions Arising from This News

• Which specific items in this dispensing remuneration revision are likely to affect our company’s revenue?
• Based on the changes in the remuneration revision, how should we review the timing and scheme of business succession?
• If the evaluations for community support system premiums and home healthcare are changed, what are the potential advantages and disadvantages of M&A?

If You Feel “Should I Consult Too?”

If you have read the news about the 2026 dispensing remuneration revision and feel concerned about the future prospects and revenue structure of your pharmacy business, it may be time to consider the possibility of third-party succession. Especially if you are struggling with a lack of successor, or find it difficult to allocate resources to respond to remuneration revisions, consulting with a specialized advisor may help you identify M&A schemes that leverage your company’s strengths and pave the way for smooth business succession.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics as a business succession support institution certified by the Small and Medium Enterprise Agency, with a full success fee system. Consultations are kept strictly confidential. Free consultation here